10 years of therapeutic advances in the rheumatic diseases
Crossref DOI link: https://doi.org/10.1038/nrrheum.2015.138
Published Online: 2015-10-13
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Isaacs, John D.
Text and Data Mining valid from 2015-10-13
Article History
First Online: 13 October 2015
Competing interests
: The author has been a member of advisory boards for Celltrion, Hospira, Janssen, Novartis, Pfizer and Roche.